Dogwood Therapeutics, Inc.

NasdaqCM:DWTX Stock Report

Market Cap: US$5.1m

Dogwood Therapeutics Management

Management criteria checks 4/4

Dogwood Therapeutics' CEO is Greg Duncan, appointed in Apr 2020, has a tenure of 4.5 years. total yearly compensation is $566.92K, comprised of 93.3% salary and 6.7% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $8.87K. The average tenure of the management team and the board of directors is 4.5 years and 3.8 years respectively.

Key information

Greg Duncan

Chief executive officer

US$566.9k

Total compensation

CEO salary percentage93.3%
CEO tenure4.5yrs
CEO ownership0.2%
Management average tenure4.5yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Aug 24
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

May 11
Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

Virios Therapeutics slides 11% postmarket on proposed stock offering

Sep 19

Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07

Aug 11

Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jun 25
Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Mar 09
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Nov 02
Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jul 19
Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Jun 04

Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Mar 31
Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Feb 01

Virios Therapeutics prices IPO at $10

Dec 17

CEO Compensation Analysis

How has Greg Duncan's remuneration changed compared to Dogwood Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$5m

Mar 31 2024n/an/a

-US$5m

Dec 31 2023US$567kUS$529k

-US$5m

Sep 30 2023n/an/a

-US$6m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$937kUS$529k

-US$12m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$1mUS$513k

-US$16m

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$17m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$4mUS$375k

-US$10m

Compensation vs Market: Greg's total compensation ($USD566.92K) is about average for companies of similar size in the US market ($USD652.28K).

Compensation vs Earnings: Greg's compensation has been consistent with company performance over the past year.

CEO

Greg Duncan (59 yo)

4.5yrs

Tenure

US$566,923

Compensation

Mr. Gregory Duncan, also known as Greg, serves as Chief Executive Officer at Dogwood Therapeutics, Inc. (formerly known as Virios Therapeutics, Inc.), (formerly Virios Therapeutics, LLC) since April 01, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Gregory Duncan
Chairman & CEO4.5yrsUS$566.92k0.17%
$ 8.9k
William Pridgen
Founder & Member of Scientific Advisory Board12.8yrsUS$42.56k2.29%
$ 117.5k
Angela Walsh
Chief Financial Officerno dataUS$282.64k0.0090%
$ 463.3
R. Gendreau
Chief Medical Officer12.8yrsUS$364.94k0%
$ 0
Ralph Grosswald
Senior Vice President of Operations4.5yrsUS$425.03kno data
Carol Duffy
Chief Scientific Advisorno datano datano data

4.5yrs

Average Tenure

59yo

Average Age

Experienced Management: DWTX's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gregory Duncan
Chairman & CEO6.8yrsUS$566.92k0.17%
$ 8.9k
William Pridgen
Founder & Member of Scientific Advisory Boardless than a yearUS$42.56k2.29%
$ 117.5k
John Thomas
Independent Director3.8yrsUS$57.56k0.0030%
$ 154.3
Ying Choi Yu
Directorno datano datano data
Richard Whitley
Member of Scientific Advisory Board & Independent Director3.8yrsUS$55.56k0.0021%
$ 108.0
David Keefer
Independent Director6.8yrsUS$64.06k0.038%
$ 2.0k
Abel De La Rosa
Independent Director3.8yrsUS$55.06k0.012%
$ 617.6
Michael Camilleri
Member of Scientific Advisory Boardno datano datano data
Daniel Clauw
Chair of Scientific Advisory Boardno datano datano data
Lesley Arnold
Member of Scientific Advisory Boardno datano datano data
Dedra Buchwald
Member of Scientific Advisory Boardno datano datano data
Joel Baines
Member of Scientific Advisory Boardno datano datano data

3.8yrs

Average Tenure

68yo

Average Age

Experienced Board: DWTX's board of directors are considered experienced (3.8 years average tenure).